A Case Report of Leptomeningeal Myelomatosis and Rapid Improvement with Regimen Consisting of Daratumumab, Pomalidomide, Vincristine, Procarbazine, and Dexamethasone

<div>MRI of leptomeningeal myelomatosis at progression of leptomeningeal myelomatosis (March 2022): (a) T1 with contrast, vertex level, (b) T1 with contrast, level at bilateral IAC lesions, and (c) T1 with contrast, cerebellum and cervical spine.</div>

Case Reports in Hematology

fig3

Figure 3

Figure 3: A Case Report of Leptomeningeal Myelomatosis and Rapid Improvement with Regimen Consisting of Daratumumab, Pomalidomide, Vincristine, Procarbazine, and Dexamethasone 

Figure 3 | A Case Report of Leptomeningeal Myelomatosis and Rapid Improvement with Regimen Consisting of Daratumumab, Pomalidomide, Vincristine, Procarbazine, and Dexamethasone 